Gossamer Bio, Inc. (GOSS) 

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Show less

Over the last 12 months, insiders at Gossamer Bio, Inc. have bought $462,534 and sold $53,578 worth of Gossamer Bio, Inc. stock.

On average, over the past 5 years, insiders at Gossamer Bio, Inc. have bought $1.07M and sold $2.97M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Hasnain Faheem (President & CEO) — $1M. Giraudo Bryan (COO/CFO) — $343,980. Milligan Sandra (director) — $25,213.

The last purchase of 372,000 shares for transaction amount of $250,282 was made by Hasnain Faheem (President & CEO) on 2024‑06‑21.